Anti-Inflammatory Therapeutics Market Size is projected to reach USD 141.58 billion by 2030, growing at a CAGR of 3.8%: Straits Research

The global anti-inflammatory therapeutics market size was valued at USD 101.21 billion in 2021. It is projected to reach USD 141.58 billion by 2030, growing at a CAGR of 3.8% during the forecast period (2022–2030). Research and development activities by major players focused on anti-inflammatory drugs and a rise in FDA approvals are expected to drive market growth.

| Source: Straits Research Straits Research

New York, United States, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Anti-inflammatory therapeutic is a drug that eases chronic pain as well as inflammation. These agents block certain substances in the body that cause inflammation. Anti-inflammatory treatments can treat sprains, rheumatoid arthritis, menstrual pain, migraines, and headaches as well as mild to moderate chronic pain. The rise in awareness of anti-inflammatory therapeutics and attractive government initiatives toward using nonsteroidal anti-inflammatory drugs are expected to augment the market growth during the forecast period.

Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/anti-inflammatory-therapeutics-market/request-sample 

Rising Incidents of Autoimmune and Respiratory Condition Drives the Global Market

A surge in chronic anti-inflammatory and autoimmune disease incidence has boosted the need for anti-inflammatory therapeutics globally. This is attributed to the fact that anti-inflammatory drugs are majorly used to treat various conditions such as arthritis, multiple sclerosis, psoriasis, asthma, COPD, anti-inflammatory bowel disease, and other nonsteroidal anti-inflammatory diseases. NSAIDs such as diclofenac, ibuprofen, and naproxen have been proven to be effective in suppressing the inflammation caused by these diseases. As the treatment and cure for autoimmune diseases are still unknown, the only possible way to ease the pain is to intake anti-inflammatory therapeutics. These factors contribute to the growth of the global market during the forecast period.

Development of Biosimilars for Existing Drugs Creates Tremendous Opportunities

Research and development activities by major players focused on anti-inflammatory drugs and a rise in FDA approvals are expected to drive market growth. For instance, in June 2020, 14 biosimilars were approved by the FDA to treat anti-inflammatory arthritis. Moreover, patented anti-inflammatory drugs are likely to face patent expiry issues, thus boosting the market for biosimilar drugs. This allows competitors to capture the market by releasing biosimilar drugs anticipating the growth of the an-inflammatory therapeutics market.

Report Scope

Report Metric Details
Market Size by 2030 USD 141.58 billion
Market Size in 2021 USD 101.21 billion
CAGR 3.8%
Historical Data 2019-2020
Base Year 2021
Forecast Period 2022-2030
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Drug Class, Indications
Geographies Covered North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors Pfizer, Inc., Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc., Novartis, F. Hoffman, La Roche AG, Eli Lily and Company, AstraZeneca PLC., and Amgen.
Key Market Opportunities Development of Biosimilars for Existing Drugs
Key Market Drivers Rising Incidents of Autoimmune and Respiratory Conditions
New Drug Pipelines

Buy Now Full Report @ https://straitsresearch.com/buy-now/anti-inflammatory-therapeutics-market 

Regional Analysis

North America is the largest shareholder in the anti-inflammatory therapeutic market and is expected to grow with a CAGR of 3.2% over the forecast period. The U.S. dominates the North American market, which can be attributed to an increasing number of people suffering from chronic conditions such as arthritis, peptic ulcers, and asthma. Moreover, factors such as a surge in the aging population, a rise in the incidence of anti-inflammatory disorders, rapid adoption of patented drugs, and established reimbursement policies are driving market growth. In addition, an increase in healthcare expenditure, a surge in the number of individuals suffering from respiratory diseases such as asthma and COPD, a large number of drugs in the pipeline, and strong patent protection coupled with a high entry barrier for generics contribute toward market growth.

Europe is projected to grow at a CAGR of 3.6%, during the forecast period. The U.K. accounted for a majority share of the market and is anticipated to continue the same trend during the forecast period. A rise in awareness among patients in European countries regarding the availability of clinical nutrition is expected to boost market growth. Moreover, due to the increase in the geriatric population suffering from bone and joint disorders, change in dietary habits coupled with a rise in the consumption of junk food and a sedentary lifestyle are key driving factors of the market growth. In addition, significant improvement in healthcare infrastructure in this region contributes to market growth.

Asia-Pacific is anticipated to grow the fastest during the forecast period. The factors driving the growth of the anti-Inflammatory therapeutic market in Asia-Pacific include a rise in healthcare spending; and an upsurge in chronic, respiratory, and infectious diseases. The regulatory scenario is further expected to contribute toward the market's growth in the region. In addition, an increase in government initiatives for the improvement of the healthcare sector and a surge in the focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities contribute toward the market growth.

Key Highlights

  • The global anti-inflammatory therapeutics market size is projected to reach USD 141.58 billion by 2030, growing at a CAGR of 3.8% during the forecast period.
  • Based on drug class, the global anti-inflammatory therapeutics market is classified into biologics, nonsteroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. The biologics segment is the highest contributor to the market and is expected to grow with a CAGR of 4.3% during the forecast period.
  • Based on indication, the global anti-inflammatory therapeutics market is fragmented into arthritis, respiratory diseases, multiple sclerosis, psoriasis, anti-inflammatory bowel disease, and other anti-inflammatory diseases. The arthritis segment owns the highest market share and is expected to grow at a CAGR of 4.6% during the forecast period.
  • North America is the largest shareholder in the anti-inflammatory therapeutic market and is expected to grow with a CAGR of 3.2% over the forecast period.

Competitors in Anti-Inflammatory Therapeutics Market

  • Pfizer Inc.
  • Abbvie Inc.
  • Johnson & Johnson
  • GlaxoSmithKline
  • Merck & CO. Inc.
  • Novartis
  • F. Hoffman
  • La Roche AG
  • Eli Lily and Company
  • AstraZeneca PLC.
  • Amgen

Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/anti-inflammatory-therapeutics-market/request-sample 

Segmentation of Anti-Inflammatory Therapeutics Market

By Drug Class

  • Nonsteroidal Anti-Inflammatory Drugs
  • Corticosteroids
  • Biologics

By Indications

  • Arthritis
  • Psoriasis
  • Respiratory Diseases
  • Multiple Sclerosis
  • Anti-inflammatory Bowel Disease
  • Others

By Regions

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

TABLE OF CONTENT

  1. EXECUTIVE SUMMARY
  2. RESEARCH SCOPE & SEGMENTATION
    1. RESEARCH OBJECTIVES
    2. MARKET DEFINITION
    3. LIMITATIONS & ASSUMPTIONS
    4. MARKET SCOPE & SEGMENTATION
    5. CURRENCY & PRICING CONSIDERED
  3. MARKET OPPORTUNITY ASSESSMENT
    1. EMERGING REGIONS / COUNTRIES
    2. EMERGING COMPANIES
    3. EMERGING APPLICATIONS / END USE
    4. INVESTMENT LANDSCAPE
    5. NEW BUSINESS MODELS / REVENUE STREAMS
    6. TAM
  4. MARKET TRENDS
    1. DRIVERS
    2. MARKET WARNING FACTORS
    3. LATEST MACRO ECONOMIC INDICATORS
    4. GEOPOLITICAL IMPACT
    5. HUMAN FACTORS
    6. TECHNOLOGY FACTORS
  5. MARKET ASSESSMENT
    1. PORTERS FIVE FORCES ANALYSIS
    2. VALUE CHAIN ANALYSIS
    3. SALES AND DISTRIBUTION CHANNEL ANALYSIS
    4. CASE STUDY ANALYSIS
    5. PATENT ANALYSIS
    6. M & A AGREEMENTS & COLLABRATION ANALYSIS
  6. ESG TRENDS
  7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE ANALYSIS
    1. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET INTRODUCTION
    2. BY DRUG CLASS
      1. INTRODUCTION
        1. DRUG CLASS BY VALUE
      2. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
        1. BY VALUE
      3. CORTICOSTEROIDS
        1. BY VALUE
      4. BIOLOGICS
        1. BY VALUE
    3. BY INDICATIONS
      1. INTRODUCTION
        1. INDICATIONS BY VALUE
      2. ARTHRITIS
        1. BY VALUE
      3. PSORIASIS
        1. BY VALUE
      4. RESPIRATORY DISEASES
        1. BY VALUE
      5. MULTIPLE SCLEROSIS
        1. BY VALUE
      6. ANTI-INFLAMMATORY BOWEL DISEASE
        1. BY VALUE
      7. OTHERS
        1. BY VALUE
  8. NORTH AMERICA MARKET ANALYSIS
    1. INTRODUCTION
    2. BY DRUG CLASS
      1. INTRODUCTION
        1. DRUG CLASS BY VALUE
      2. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
        1. BY VALUE
      3. CORTICOSTEROIDS
        1. BY VALUE
      4. BIOLOGICS
        1. BY VALUE
    3. BY INDICATIONS
      1. INTRODUCTION
        1. INDICATIONS BY VALUE
      2. ARTHRITIS
        1. BY VALUE
      3. PSORIASIS
        1. BY VALUE
      4. RESPIRATORY DISEASES
        1. BY VALUE
      5. MULTIPLE SCLEROSIS
        1. BY VALUE
      6. ANTI-INFLAMMATORY BOWEL DISEASE
        1. BY VALUE
      7. OTHERS
        1. BY VALUE
    4. U.S.
      1. BY DRUG CLASS
        1. INTRODUCTION
          1. DRUG CLASS BY VALUE
        2. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
          1. BY VALUE
        3. CORTICOSTEROIDS
          1. BY VALUE
        4. BIOLOGICS
          1. BY VALUE
      2. BY INDICATIONS
        1. INTRODUCTION
          1. INDICATIONS BY VALUE
        2. ARTHRITIS
          1. BY VALUE
        3. PSORIASIS
          1. BY VALUE
        4. RESPIRATORY DISEASES
          1. BY VALUE
        5. MULTIPLE SCLEROSIS
          1. BY VALUE
        6. ANTI-INFLAMMATORY BOWEL DISEASE
          1. BY VALUE
        7. OTHERS
          1. BY VALUE
    5. CANADA
  9. EUROPE MARKET ANALYSIS
    1. INTRODUCTION
    2. BY DRUG CLASS
      1. INTRODUCTION
        1. DRUG CLASS BY VALUE
      2. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
        1. BY VALUE
      3. CORTICOSTEROIDS
        1. BY VALUE
      4. BIOLOGICS
        1. BY VALUE
    3. BY INDICATIONS
      1. INTRODUCTION
        1. INDICATIONS BY VALUE
      2. ARTHRITIS
        1. BY VALUE
      3. PSORIASIS
        1. BY VALUE
      4. RESPIRATORY DISEASES
        1. BY VALUE
      5. MULTIPLE SCLEROSIS
        1. BY VALUE
      6. ANTI-INFLAMMATORY BOWEL DISEASE
        1. BY VALUE
      7. OTHERS
        1. BY VALUE
    4. U.K.
      1. BY DRUG CLASS
        1. INTRODUCTION
          1. DRUG CLASS BY VALUE
        2. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
          1. BY VALUE
        3. CORTICOSTEROIDS
          1. BY VALUE
        4. BIOLOGICS
          1. BY VALUE
      2. BY INDICATIONS
        1. INTRODUCTION
          1. INDICATIONS BY VALUE
        2. ARTHRITIS
          1. BY VALUE
        3. PSORIASIS
          1. BY VALUE
        4. RESPIRATORY DISEASES
          1. BY VALUE
        5. MULTIPLE SCLEROSIS
          1. BY VALUE
        6. ANTI-INFLAMMATORY BOWEL DISEASE
          1. BY VALUE
        7. OTHERS
          1. BY VALUE
    5. GERMANY
    6. FRANCE
    7. SPAIN
    8. ITALY
    9. RUSSIA
    10. NORDIC
    11. BENELUX
    12. REST OF EUROPE
  10. APAC MARKET ANALYSIS
    1. INTRODUCTION
    2. BY DRUG CLASS
      1. INTRODUCTION
        1. DRUG CLASS BY VALUE
      2. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
        1. BY VALUE
      3. CORTICOSTEROIDS
        1. BY VALUE
      4. BIOLOGICS
        1. BY VALUE
    3. BY INDICATIONS
      1. INTRODUCTION
        1. INDICATIONS BY VALUE
      2. ARTHRITIS
        1. BY VALUE
      3. PSORIASIS
        1. BY VALUE
      4. RESPIRATORY DISEASES
        1. BY VALUE
      5. MULTIPLE SCLEROSIS
        1. BY VALUE
      6. ANTI-INFLAMMATORY BOWEL DISEASE
        1. BY VALUE
      7. OTHERS
        1. BY VALUE
    4. CHINA
      1. BY DRUG CLASS
        1. INTRODUCTION
          1. DRUG CLASS BY VALUE
        2. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
          1. BY VALUE
        3. CORTICOSTEROIDS
          1. BY VALUE
        4. BIOLOGICS
          1. BY VALUE
      2. BY INDICATIONS
        1. INTRODUCTION
          1. INDICATIONS BY VALUE
        2. ARTHRITIS
          1. BY VALUE
        3. PSORIASIS
          1. BY VALUE
        4. RESPIRATORY DISEASES
          1. BY VALUE
        5. MULTIPLE SCLEROSIS
          1. BY VALUE
        6. ANTI-INFLAMMATORY BOWEL DISEASE
          1. BY VALUE
        7. OTHERS
          1. BY VALUE
    5. KOREA
    6. JAPAN
    7. INDIA
    8. AUSTRALIA
    9. TAIWAN
    10. SOUTH EAST ASIA
    11. REST OF ASIA-PACIFIC
  11. MIDDLE EAST AND AFRICA MARKET ANALYSIS
    1. INTRODUCTION
    2. BY DRUG CLASS
      1. INTRODUCTION
        1. DRUG CLASS BY VALUE
      2. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
        1. BY VALUE
      3. CORTICOSTEROIDS
        1. BY VALUE
      4. BIOLOGICS
        1. BY VALUE
    3. BY INDICATIONS
      1. INTRODUCTION
        1. INDICATIONS BY VALUE
      2. ARTHRITIS
        1. BY VALUE
      3. PSORIASIS
        1. BY VALUE
      4. RESPIRATORY DISEASES
        1. BY VALUE
      5. MULTIPLE SCLEROSIS
        1. BY VALUE
      6. ANTI-INFLAMMATORY BOWEL DISEASE
        1. BY VALUE
      7. OTHERS
        1. BY VALUE
    4. UAE
      1. BY DRUG CLASS
        1. INTRODUCTION
          1. DRUG CLASS BY VALUE
        2. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
          1. BY VALUE
        3. CORTICOSTEROIDS
          1. BY VALUE
        4. BIOLOGICS
          1. BY VALUE
      2. BY INDICATIONS
        1. INTRODUCTION
          1. INDICATIONS BY VALUE
        2. ARTHRITIS
          1. BY VALUE
        3. PSORIASIS
          1. BY VALUE
        4. RESPIRATORY DISEASES
          1. BY VALUE
        5. MULTIPLE SCLEROSIS
          1. BY VALUE
        6. ANTI-INFLAMMATORY BOWEL DISEASE
          1. BY VALUE
        7. OTHERS
          1. BY VALUE
    5. TURKEY
    6. SAUDI ARABIA
    7. SOUTH AFRICA
    8. EGYPT
    9. NIGERIA
    10. REST OF MEA
  12. LATAM MARKET ANALYSIS
    1. INTRODUCTION
    2. BY DRUG CLASS
      1. INTRODUCTION
        1. DRUG CLASS BY VALUE
      2. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
        1. BY VALUE
      3. CORTICOSTEROIDS
        1. BY VALUE
      4. BIOLOGICS
        1. BY VALUE
    3. BY INDICATIONS
      1. INTRODUCTION
        1. INDICATIONS BY VALUE
      2. ARTHRITIS
        1. BY VALUE
      3. PSORIASIS
        1. BY VALUE
      4. RESPIRATORY DISEASES
        1. BY VALUE
      5. MULTIPLE SCLEROSIS
        1. BY VALUE
      6. ANTI-INFLAMMATORY BOWEL DISEASE
        1. BY VALUE
      7. OTHERS
        1. BY VALUE
    4. BRAZIL
      1. BY DRUG CLASS
        1. INTRODUCTION
          1. DRUG CLASS BY VALUE
        2. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
          1. BY VALUE
        3. CORTICOSTEROIDS
          1. BY VALUE
        4. BIOLOGICS
          1. BY VALUE
      2. BY INDICATIONS
        1. INTRODUCTION
          1. INDICATIONS BY VALUE
        2. ARTHRITIS
          1. BY VALUE
        3. PSORIASIS
          1. BY VALUE
        4. RESPIRATORY DISEASES
          1. BY VALUE
        5. MULTIPLE SCLEROSIS
          1. BY VALUE
        6. ANTI-INFLAMMATORY BOWEL DISEASE
          1. BY VALUE
        7. OTHERS
          1. BY VALUE
    5. MEXICO
    6. ARGENTINA
    7. CHILE
    8. COLOMBIA
    9. REST OF LATAM
  13. COMPETITIVE ASSESSMENT
    1. ADOPTION MATRIX
    2. ANTI-INFLAMMATORY THERAPEUTICS MARKET SHARE BY MANUFACTURERS
    3. ANTI-INFLAMMATORY THERAPEUTICS MARKET RANKING BY REVENUE FOR MANUFACTURERS
    4. AVERAGE PRICE BY MANUFACTURERS
    5. VENDOR FOOTPRINT ANALYSIS
  14. MARKET PLAYERS ASSESSMENT
    1. PFIZER, INC.
      1. OVERVIEW
      2. BUSINESS INFORMATION
      3. REVENUE
      4. ASP
      5. GROSS MARGIN
      6. SWOT ANALYSIS
      7. RECENT DEVELOPMMENTS
    2. ABBVIE, INC.
    3. JOHNSON & JOHNSON
    4. GLAXOSMITHKLINE
    5. MERCK & CO., INC
    6. NOVARTIS
    7. HOFFMAN
    8. LA ROCHE AG
    9. ELI LILY AND COMPANY
    10. ASTRAZENECA PLC
    11. AMGEN
  15. RESEARCH METHODOLOGY
    1. RESEARCH DATA
      1. SECONDARY DATA
        1. MAJOR SECONDARY SOURCES
        2. KEY DATA FROM SECONDARY SOURCES
      2. PRIMARY DATA
        1. KEY DATA FROM PRIMARY SOURCES
        2. BREAKDOWN OF PRIMARIES
      3. SECONDARY AND PRIMARY RESEARCH
        1. KEY INDUSTRY INSIGHTS
    2. MARKET SIZE ESTIMATION
      1. BOTTOM-UP APPROACH
      2. TOP-DOWN APPROACH
      3. MARKET PROJECTION
    3. RESEARCH ASSUMPTIONS
      1. ASSUMPTIONS
    4. LIMITATIONS
    5. RISK ASSESSMENT
  16. APPENDIX
    1. DISCUSSION GUIDE
    2. CUSTOMIZATION OPTIONS
    3. RELATED REPORTS
  17. DISCLAIMER

Table of Content and Figure @ https://straitsresearch.com/report/anti-inflammatory-therapeutics-market/toc

Recent Development

  • In June 2022, Pfizer and Roivant Sciences formed a company to develop anti-inflammatory drugs. The new biotech, Priovant Therapeutics, will advance two Pfizer treatments for autoimmune conditions. Pfizer will own 25% of Priovant.
  • In June 2021, GlaxoSmithKline plc and iTeos Therapeutics announced an agreement to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody, as a potential treatment for patients with cancer.

News Media

Global Anti-Inflammatory Therapeutics Market Grows Steadily at a CAGR of 4%

Have a Look at the Related Research Report

 Acute Wound Care Market: Information by Product (Advanced Wound Dressing, Surgical Wound Care), Application (Chronic Wounds and Acute Wounds), End-User, and Region — Forecast till 2030

Osteoarthritis Treatment Market: Information by Drugs (Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids), Anatomy (Ankle Osteoarthritis), and Region – Forecast till 2030

Autoimmune Disease Diagnostics Market: Information by Disease Type (Systemic Autoimmune Disease), Diagnosis (Antinuclear Antibody Tests, Autoantibody Tests), and Region — Forecast till 2030

Autoimmune Therapeutics Market: Information by Drug Class (Corticosteroids), Disease Type (Rheumatoid Arthritis), Distribution Channel (Retail Pharmacies), and Region — Forecast till 2029

Respiratory Protective Equipment Market: Information by Product (Air Purifying Respirator, Supplied Air Respirator), End-User (Industrial, Healthcare), and Region—Forecast till 2031

About Straits Research Pvt. Ltd.

Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

For more information on your target market, please contact us below:

Phone: +1 646 480 7505 (the U.S.)

+91 8087085354 (APAC)

+44 208 068 9665 (the U.K.)

Email: sales@straitsresearch.com

Follow Us: LinkedIn | Facebook | Instagram | Twitter


Tags

Anti-Inflammatory Therapeutics chronic pain anti-inflammatory drugs anti-inflammatory biologics Corticosteroids biologics COPD

Related Links